

20-EPI-VITAMIN D₃ ANALOGUES: A NOVEL CLASS OF POTENT REGULATORS OF CELL GROWTH AND IMMUNE RESPONSES

L. BINDERUP,*† S. LATINI,* E. BINDERUP,‡ C. BRETTING,‡ M. CALVERLEY‡
and K. HANSEN‡

Departments of *Biology and ‡Chemical Research, Leo Pharmaceutical Products,
DK-2750 Ballerup, Denmark

(Received 6 March 1991; accepted 8 June 1991)

Abstract—The 20-epi-vitamin D₃ analogues are a novel class of vitamin D₃ derivatives, structurally related to 1 α ,25-dihydroxycholecalciferol (1 α ,25(OH)₂D₃). They are characterized by an altered stereochemistry at carbon 20 in the side-chain. *In vitro*, these new analogues were found to be considerably more potent as regulators of growth and differentiation in the human histiocytic lymphoma cell line U 937 than 1 α ,25(OH)₂D₃, despite a practically unchanged calcemic activity *in vivo*. The most potent analogue, KH 1060, inhibited cell proliferation by 50% at 10⁻¹² M (14,000 times more active than 1 α ,25(OH)₂D₃). At the same time, KH 1060 induced cell differentiation at concentrations as low as 10⁻¹⁴ M. In addition, the 20-epi-vitamin D₃ analogues were found to be very potent inhibitors of T-lymphocyte proliferation induced by interleukin-1 or alloantigen. In this respect, they were several orders of magnitude more active than the potent immunosuppressive agent cyclosporin A (CyA). KH 1060, the most potent analogue, inhibited interleukin-1-induced mouse thymocyte proliferation by 50% at 3 \times 10⁻¹⁶ M and allogeneic stimulation of mouse spleen lymphocytes at 5 \times 10⁻¹⁵ M. These effects were considered to be mediated by inhibition of interleukin-2 release from activated T-lymphocytes. The new analogues are of potential interest in the prevention of graft rejection and in the treatment of psoriasis, cancer and auto-immune diseases.

In recent years, the physiologically active metabolite of vitamin D₃, 1 α ,25-dihydroxycholecalciferol [1 α ,25(OH)₂D₃], has achieved status as a hormone with effects on cell growth and cell differentiation, in addition to its well-known role in calcium homeostasis [1]. The effects of 1 α ,25(OH)₂D₃ are believed to be mediated via binding to a specific receptor that belongs to the family of nuclear receptors for glucocorticoids, estrogens, thyroxine and retinoic acid [2, 3].

The therapeutic potential of 1 α ,25(OH)₂D₃ and its synthetic analogue 1 α -hydroxycholecalciferol has been investigated in cancer and psoriasis [4–6]. However, the strong calcemic activity of these compounds limits their clinical usefulness [7] and an intensive research activity has therefore been directed at finding new vitamin D analogues with a more favourable therapeutic profile. As a first step in this direction, the recent development of the new analogue calcipotriol (MC 903) [8–10] has led to an effective and safe topical treatment of psoriasis vulgaris [11, 12]. Other new analogues have been reported to increase survival of leukemic mice [13] and to regulate immune responses [14], with a decreased risk of inducing calcemic side-effects.

The present investigation reports the biological activities of a new series of vitamin D₃ analogues, characterized by an altered stereochemistry at carbon 20 (C20). These novel 20-epi-vitamin D₃ analogues were investigated *in vitro* for their effects on cancer cell growth and differentiation, using the human histiocytic lymphoma cell line U 937, which displays

high affinity receptors for 1 α ,25(OH)₂D₃ [15]. These new analogues were also tested for their ability to affect calcium homeostasis *in vivo* after oral administration to rats and for their binding to the intestinal receptor for 1 α ,25(OH)₂D₃, which mediates calcium uptake from the intestine [1].

Finally, the 20-epi-vitamin D₃ analogues were assessed for their effects on T-lymphocyte activation *in vitro*. Previous studies have shown that monocytes, macrophages and activated lymphocytes possess receptors for 1 α ,25(OH)₂D₃ [16]. In analogy with the potent immunosuppressive agent cyclosporin A (CyA), 1 α ,25(OH)₂D₃ has been shown to inhibit proliferation of activated T-lymphocytes, presumably by interfering with IL-1/IL-2 and other cytokine-mediated functions [17, 18]. It was therefore considered of interest to investigate the effects of the new analogues on cytokine-mediated T-cell activation, in comparison with 1 α ,25(OH)₂D₃ and CyA.

MATERIALS AND METHODS

Chemicals. 1 α ,25(OH)₂D₃ and analogues modified in the side-chain were synthesized in the Department of Chemical Research, Leo Pharmaceutical Products. The methods of synthesis are described in the patent applications Nos. WO 89/10351, PCT/DK 90/00186, WO 90/09991 and WO 90/09992. Cyclosporin A (CyA) was a gift from Sandoz (Basle, Switzerland). The vitamin D₃ derivatives were dissolved in isopropanol or dimethyl sulphoxide, and CyA was dissolved in absolute ethanol for the *in vitro* studies. The solutions were stored at –20°. For *in vivo*

† To whom correspondence should be addressed.

Table 4. Inhibitory effects of selected 20-epi-vitamin D₃ analogues and CyA on allogeneic T-cell activation

Compound code name	Cell proliferation [³ H]TdR uptake IC ₅₀ (M)	Potency relative to 1 α ,25(OH) ₂ D ₃
1 α ,25(OH) ₂ D ₃ *	5.2×10^{-11}	1
MC 1288	1.9×10^{-13}	274
EB 1231	3.2×10^{-13}	163
MC 1301	2.2×10^{-14}	2364
CB 966*	9.5×10^{-12}	5
KH 1060	4.9×10^{-15}	10,612
KH 1139*	2.7×10^{-12}	19
CyA	4.4×10^{-9}	0.01

Spleen lymphocytes from Balb/c and CB6F₁ mice were adjusted to 2.5×10^6 cells/mL. Mixed cell cultures containing 100 μ L of each cell suspension were incubated for 144 hr. Addition of test compounds and assessment of proliferation were performed as described in the legend to Table 3.

* Reference compounds with normal stereochemistry at C20.

regulation *in vitro* were identified. These new analogues, characterized by an altered stereochemistry at carbon 20 in the side-chain (20-epi-vitamin D₃ analogues), were considerably more potent *in vitro* than 1 α ,25(OH)₂D₃. The reasons for this increased potency are not known. One possibility is that the new analogues may bind with higher affinity to the 1 α ,25(OH)₂D₃ receptor in cells responding to their growth regulatory activity than to the receptor in the cells that mediate calcium uptake from the gut. However, data obtained with the most potent analogue, KH 1060, showed that this analogue bound with similar affinity to receptor preparations from intestinal cells and from a number of cultured tumour cells (including the U 937 cells). It is therefore more likely that the increased potency is associated with post-receptor binding effects, such as increased metabolic stability of the receptor-drug complex or higher affinity for the DNA-binding site [26].

The 20-epi-vitamin D₃ analogues, when tested in rats to assess their effects *in vivo* on calcium metabolism, were found to exert calcemic effects comparable to those of 1 α ,25(OH)₂D₃. These findings correlate reasonably well with the binding of the various compounds to the intestinal receptor for 1 α ,25(OH)₂D₃, but are nevertheless surprising in view of their strong, direct effects on cell differentiation and cell proliferation. In order to establish the potential clinical usefulness of these new analogues, a number of additional studies on their effects on calcium metabolism are indicated. These include studies on calcium transport *in vitro*, using the everted gut-sac technique [27] and studies on bone calcium mobilization *in vivo* [28]. In addition, pharmacokinetic studies are needed to establish the rate of metabolism and the structure and activity of any metabolites.

In addition to their ability to regulate cell growth and differentiation of U 937 cells, the 20-epi-vitamin

D₃ analogues were also tested for their effects on T-lymphocyte activation *in vitro*. This was done in comparison with the widely used immunosuppressive agent CyA, using test systems previously shown to be relevant in the study of the mechanism of action of this agent. These tests include measurement of the release of IL-1 and IL-2 from human peripheral blood cells and studies of T-cell activation by IL-1 or alloantigen in murine thymocytes and spleen lymphocytes [29].













In the present experiments, 1 α ,25(OH)₂D₃ and the 20-epi-vitamin D₃ analogues were not able to inhibit one of the first events in the processes leading to T-cell activation, namely the release of IL-1 β from accessory cells. However, these results should be interpreted with caution as previous studies with 1 α ,25(OH)₂D₃ in the same type of test system have shown increased, decreased or unaffected IL-1 secretion [16, 30, 31], suggesting that small changes in the culture conditions may result in varying responses.

In contrast, CyA, 1 α ,25(OH)₂D₃ and the 20-epi-vitamin D₃ analogues inhibited IL-1 or alloantigen-mediated T-cell activation, the latter being by far the most potent inhibitors. No inhibition was observed in cells stimulated with IL-2. This type of response has previously been described for CyA and 1 α ,25(OH)₂D₃ [17, 29, 31, 32]. In addition, both CyA and the vitamin D₃ derivatives inhibited IL-2 release from stimulated T-cells. These findings suggest that despite very different types of receptors (cyclophilin for CyA [33] and the steroid-type receptor [2] for 1 α ,25(OH)₂D₃), the 20-epi-vitamin D₃ analogues exhibit a number of similarities with CyA. These effects may be mediated by inhibition of IL-2 production in T-lymphocytes, through regulation of gene transcription, as described previously for CyA and 1 α ,25(OH)₂D₃ [34, 35]. Alternatively, both types of compound may act via a calcium-mediated pathway. The early events in T-cell activation are calcium-dependent and CyA has been shown to inhibit calmodulin [36], whereas 1 α ,25(OH)₂D₃ is able to regulate intracellular free calcium levels [37].

In conclusion, we believe that the 20-epi-vitamin D₃ analogues, and in particular KH 1060, are amongst the most potent regulators of cell growth, differentiation and cytokine-mediated T-lymphocyte activation studied so far. Further studies are needed to investigate the effects of these analogues *in vitro* and *in vivo*. Preliminary experiments performed with i.p. administration of KH 1060 have shown that the compound significantly prolongs mouse skin allograft survival at doses as low as 0.02 μ g/kg/day (J. L. Touraine and P. Veyron, Transplantation and Clinical Immunology Centre, Hôpital Edouard Herriot, Lyon, France) and prevents autoimmune glomerulonephritis in BN rats injected with HgCl₂ at 0.03 μ g/kg/day (S. T. Lillevang, Dept. Immunology, Odense University Hospital, Denmark) (personal communications, manuscripts in preparation). These novel analogues may be of therapeutic interest in the prevention of graft rejection and in the treatment of psoriasis, cancer and autoimmune diseases.

Acknowledgements—Assistance with the synthesis of the

Table 1. Structure-activity relationship of 20-epi-vitamin D₃ analogues

					
Structure R	Compound code name	Inhibition of cell proliferation IC ₅₀ (M)	Induction of cell differentiation (M)	Receptor binding 50% displacement (M)	Calcemic activity relative to 1 α ,25(OH) ₂ D ₃
	1 α ,25(OH) ₂ D ₃ *	1.4×10^{-8}	2.0×10^{-9}	1.6×10^{-11}	1.0
	MC 1288	2.8×10^{-10}	7.5×10^{-11}	1.3×10^{-11}	2.3
	EB 1231	4.4×10^{-11}	1.0×10^{-11}	1.4×10^{-11}	5.0
	MC 1301	8.2×10^{-11}	1.0×10^{-11}	1.6×10^{-11}	1.2
	CB 966*	1.7×10^{-9}	4.0×10^{-10}	9.0×10^{-11}	0.2
	MC 1292	3.4×10^{-9}	5.0×10^{-10}	7.3×10^{-10}	0.1
	KH 1059	1.7×10^{-10}	1.7×10^{-12}	1.8×10^{-10}	2.7
	KH 1060	1.0×10^{-12}	1.0×10^{-14}	1.3×10^{-11}	1.3
	KH 1139*	1.4×10^{-10}	1.0×10^{-10}	5.0×10^{-11}	0.3
	KH 1049	4.2×10^{-11}	5.0×10^{-12}	4.5×10^{-11}	1.4
	KH 1067	5.0×10^{-11}	5.0×10^{-12}	2.6×10^{-11}	0.8

U 937 cells (1×10^5 cells/mL) were cultured for 96 hr in the presence of 1 α ,25(OH)₂D₃ or vitamin D₃ analogues (10^{-14} – 10^{-7} M). All compounds were tested in three separate experiments. Cell proliferation was determined by cell counting and the inhibitory effects were expressed as IC₅₀ values. Cell differentiation was assessed by the histochemical evaluation of membrane-associated esterase activity. Binding to the 1 α ,25(OH)₂D₃ receptor from rachitic chicken intestine was measured by displacement of [³H]1 α ,25(OH)₂D₃. Calcemic activity was measured in Lewis rats, as the increase in urinary calcium excretion from day 3 to 7 of a 7 day treatment period with 1 α ,25(OH)₂D₃ (0.5 μ g/kg/day p.o.) or vitamin D analogues (0.1–10 μ g/kg/day p.o.). The calcemic activity of the analogues was calculated in relation to that of 1 α ,25(OH)₂D₃. Calcium concentrations in urine were 18.4 ± 1.5 μ mol/day in control rats and 89.1 ± 7.8 μ mol/day in rats treated with 0.5 μ g/kg/day 1 α ,25(OH)₂D₃ (N = 10, mean \pm SEM).

* Reference compounds with normal stereochemistry at C20.

consisted of three rats. The rats were placed in metabolism cages and urine was collected daily. Calcium in urine was determined by complex formation with o-cresolphthalein. The urinary excretion of calcium was calculated from day 3 to 7 of the experiment (steady-state conditions). The dosage resulting in an excretion of calcium

comparable to that measured in rats given 0.5 μ g/kg/day of 1 α ,25(OH)₂D₃ was calculated from the dose-response curve and expressed in relation to 1 α ,25(OH)₂D₃. The choice of the 1 α ,25(OH)₂D₃ dosage of 0.5 μ g/kg/day was based on a full-scale dose-response experiment (0.01–10 μ g/kg/day 1 α ,25(OH)₂D₃).

RESULTS

Structure-activity relationship of 20-epi-vitamin D₃ analogues

Table 1 shows a series of new vitamin D₃ derivatives, characterized by an altered stereochemistry at C20. The human histiocytic lymphoma cell line U 937 was used to evaluate the effects of these derivatives on cell growth and differentiation. Upon incubation with 1 α ,25(OH)₂D₃, the rate of cell proliferation was decreased (IC₅₀ = 1.4 \times 10⁻⁸ M), and cell differentiation was induced (at 2.0 \times 10⁻⁹ M).

20-Epi-1 α ,25(OH)₂D₃ (MC 1288) was 50 times more active as an inhibitor of cell proliferation and 25 times more active as an inducer of cell differentiation than 1 α ,25(OH)₂D₃ itself. Compared to MC 1288, elongation of the side-chain led to a further increase in activity (EB 1231), whereas the introduction of an oxygen atom at position 22 decreased the activity (MC 1292). However, by increasing the side-chain length of MC 1292 and replacing the C26 methyl groups with ethyl groups, an analogue (KH 1060) which was 14,000 times more active than 1 α ,25(OH)₂D₃ in inhibiting U 937 cell proliferation was obtained. The shape of the dose-response curves for all the tested analogues was similar to that obtained with 1 α ,25(OH)₂D₃. The maximum inhibition of cell proliferation, compared to control cultures, was 80%.

In the same cultures, KH 1060 induced cell differentiation in concentrations as low as 10⁻¹⁴ M. Compounds with "normal" stereochemistry at C20 were always less active than the corresponding 20-epimers (compare MC 1288/1 α ,25(OH)₂D₃, MC 1301/CB 966 and KH 1060/KH 1139). Elongation of the side-chains of KH 1059 and KH 1060 led to analogues with decreased activity (KH 1049 and KH 1067). None of the compounds affected cell viability, as established by eosin Y exclusion.

The binding affinity of most of the 20-epi analogues to the chicken intestinal receptor for 1 α ,25(OH)₂D₃ was close to that of 1 α ,25(OH)₂D₃ (Table 1). In order to investigate whether the 20-epi analogues might exhibit an altered binding affinity to 1 α ,25(OH)₂D₃ receptors in cell types other than epithelial intestinal cells receptor preparations were obtained from suspensions of human U 937 cells, human T-47D breast carcinoma cells and rat osteosarcoma M1-OS/C42 cells. The presence of 1 α ,25(OH)₂D₃ receptors in these cells was verified by sucrose-gradient centrifugation with [³H]-1 α ,25(OH)₂D₃. Table 2 shows the results obtained with 1 α ,25(OH)₂D₃ and KH 1060. Both compounds exhibited similar binding affinity in all cell types, close to that observed with the intestinal receptor. KH 1060 was, however, considerably more potent than 1 α ,25(OH)₂D₃ in inhibiting cell proliferation in the tumour cell lines than 1 α ,25(OH)₂D₃ (Table 2).

The ability of 20-epi analogues to affect calcium metabolism *in vivo* was studied next. Table 1 shows that most of the analogues were comparable to 1 α ,25(OH)₂D₃ in their ability to increase urinary calcium excretion in rats during a 7 day dosing period. Measurement of serum calcium levels on day 7 showed the same relationship, but this

parameter was less sensitive in detecting small changes in the vitamin D activity than the urinary calcium assay (results not shown).

Effects of 20-epi-vitamin D₃ analogues on T-cell activation

The release of IL-1 from LPS-stimulated human peripheral blood mononuclear cells was first investigated. IL-1 release was determined by RIA, based on the detection of IL-1 β , the major form of IL-1 released from human monocytes [24]. No inhibitory effects of 1 α ,25(OH)₂D₃, CyA or any of the 20-epi-vitamin D₃ analogues were observed in this system, in concentrations up to 10⁻⁷ M (results not shown).

In contrast, 1 α ,25(OH)₂D₃, CyA and the 20-epi-vitamin D₃ analogues inhibited the proliferative response of mouse thymocytes stimulated with IL-1 and sub-optimal amounts of PHA. The 20-epi analogues were considerably more potent than the corresponding derivatives with normal stereochemistry at C20. KH 1060 was the most potent analogue, approximately 600,000 times more active than 1 α ,25(OH)₂D₃ (Table 3).

Interference with the IL-1 induced proliferative response may be due to a reduction in IL-2 production/release. To test this hypothesis, KH 1060, as the most potent compound, was assayed for its ability to inhibit the release of IL-2 from PHA-stimulated human peripheral blood mononuclear cells. Fifty per cent inhibition was observed with KH 1060 at 3 \times 10⁻¹⁴ M, with 1 α ,25(OH)₂D₃ at 1 \times 10⁻⁹ M and with CyA at 1 \times 10⁻⁹ M (Fig. 1). Furthermore, thymocytes activated by IL-2 and PHA were not inhibited by 1 α ,25(OH)₂D₃ or by any of the 20-epi-vitamin D₃ analogues in concentrations up to 10⁻⁸ M (results not shown).

These results suggest that the 20-epi-vitamin D₃ analogues, in analogy with CyA, might be useful in suppressing T-cell activation signals and thereby prevent rejection of transplanted tissues. *In vitro*, the mixed lymphocyte reaction (MLR) mimics the proliferative response to foreign histocompatibility antigens that occurs during the process of allograft rejection *in vivo* [21]. Table 4 shows that the 20-epi-vitamin D₃ analogues in concentrations from 10⁻¹² to 10⁻¹⁵ M inhibited allogeneic stimulation in cultures of spleen cells from Balb/c and CB6F₁ mice. KH 1060 was again the most potent analogue (IC₅₀ = 5 \times 10⁻¹⁵ M). 1 α ,25(OH)₂D₃ and CyA inhibited the MLR at 5 \times 10⁻¹¹ M and 4 \times 10⁻⁹ M, respectively. Addition of IL-2 (250 units/mL) completely counteracted the inhibitory effects of KH 1060, 1 α ,25(OH)₂D₃ and CyA in the MLR.

DISCUSSION

The recent discovery of the ability of 1 α ,25(OH)₂D₃ to regulate growth and differentiation in many cell types, including cancer cells, epidermal keratinocytes and activated cells of the immune system [1], has set the stage for the development of a class of novel agents with potential usefulness in hyperproliferative and immune-mediated diseases. Ideally, such agents should possess potent effects as regulators of cell growth and differentiation at concentrations well

Table 2. Effects of KH 1060 on tumour cell proliferation and receptor binding: comparison with 1 α ,25(OH)₂D₃

Compound	Tumour cell line (species)	Inhibition of cell proliferation IC ₅₀ (M)	Receptor binding 50% displacement (M)
1 α ,25(OH) ₂ D ₃	U 937	1.4×10^{-8}	2.8×10^{-11}
KH 1060	Histiocytic lymphoma (human)	1.0×10^{-12}	2.5×10^{-11}
1 α ,25(OH) ₂ D ₃	T-47D	1.1×10^{-9}	5.5×10^{-11}
KH 1060	Breast carcinoma (human)	1.4×10^{-12}	5.0×10^{-11}
1 α ,25(OH) ₂ D ₃	M1-OS/C42	7.1×10^{-9}	1.6×10^{-11}
KH 1060	Osteosarcoma (rat)	8.9×10^{-13}	1.3×10^{-11}

1 α ,25(OH)₂D₃ or KH 1060 (10^{-13} – 10^{-7} M) was added to cultures of U 937 cells (1×10^5 cells/mL, culture time 96 hr) and to cultures of T-47D and M1-OS/C42 cells (5×10^4 cells/mL, culture time 168 hr). Proliferation was assessed by cell counting (U 937 cells) or [³H]TdR uptake (T-47D and M1-OS/C42 cells). Receptor preparations were obtained from homogenates of the cells and receptor binding was measured by displacement of [³H]1 α ,25(OH)₂D₃. Results are the mean of three experiments.

Table 3. Inhibitory effects of selected 20-epi-vitamin D₃ analogues and CyA on murine thymocyte activation

Compound code name	Cell proliferation [³ H]TdR uptake IC ₅₀ (M)	Potency relative to 1 α ,25(OH) ₂ D ₃
1 α ,25(OH) ₂ D ₃ *	1.9×10^{-10}	1
MC 1288	2.6×10^{-14}	7308
EB 1231	5.0×10^{-13}	380
MC 1301	6.7×10^{-15}	28,358
CB 966*	1.0×10^{-11}	19
KH 1060	3.0×10^{-16}	633,333
KH 1139*	2.1×10^{-11}	9
CyA	7.5×10^{-9}	0.03

Thymocytes from Balb/c mice (5×10^6 cells/mL) were stimulated with IL-1 (2.5 units/mL) and PHA (10 μ g/mL). 1 α ,25(OH)₂D₃, vitamin D₃ analogues or CyA were added and the cultures were incubated for 72 hr. Proliferation was assessed by [³H]TdR uptake during the last 4 hr of incubation. Inhibitory effects were expressed as IC₅₀ values (mean of three experiments). The potency of the vitamin D₃ analogues was calculated in relation to that of 1 α ,25(OH)₂D₃.

* Reference compounds with normal stereochemistry at C20.




Fig. 1. Inhibitory effects of 1 α ,25(OH)₂D₃, KH 1060 and CyA on IL-2 release from PHA-stimulated human peripheral blood mononuclear cells (PBMC). PBMC were obtained by density sedimentation on Lymphoprep. The cells were adjusted to 2.5×10^6 cells/mL and incubated with PHA (20 μ g/mL), and test compounds for 24 hr. Cell supernatants were assayed for IL-2 content, using purified CD3⁺ T-cells obtained from human PBMC by binding to particle-bound anti-CD3 monoclonal antibody. All cultures were performed in triplicate.

below those that may induce side-effects related to the classical vitamin D activity on calcium absorption and bone mineralization.

In the present investigation, we have used the human histiocytic lymphoma cell line U 937 [15] to determine the effects of new vitamin D₃ analogues on cell growth and differentiation *in vitro*. This cell line has, along with the human promyelocytic leukemia HL-60 cell line, been used extensively in the study of structure-activity relationships of vitamin D metabolites and analogues [25]. In the presence of 1 α ,25(OH)₂D₃, the rate of proliferation of the U 937 cells is decreased and the cells

differentiate along the monocyte-macrophage pathway, as assessed by the appearance of membrane-associated esterase activity. We have tested more than 200 new vitamin D₃ analogues in this system, over a period of 4 years. Analogues which were more potent than 1 α ,25(OH)₂D₃ were further assayed for their ability to bind to the 1 α ,25(OH)₂D₃ receptor, isolated from the intestinal epithelium of rachitic chickens, and for their ability to interfere with calcium homeostasis (induction of hypercalciuria in rats).

Using this approach, a series of new vitamin D₃ analogues with potent effects on cell growth

studies, solutions were prepared in propylene glycol and kept at 4° for a maximum of 7 days.

Effects on cancer cells in vitro. Studies on cell proliferation and differentiation were performed using the human histiocytic lymphoma cell line U 937, as described previously [9]. U 937 cells were adjusted to 1×10^5 cells/mL in RPMI 1640 (Gibco, U.S.A.). The medium was supplemented with 2 mM glutamine, 100 units/mL penicillin, 100 µg/mL streptomycin and 10% fetal calf serum (FCS, Gibco). Cells (5 mL) were incubated for 96 hr at 37° in the presence of vitamin D₃ derivatives (10^{-14} – 10^{-7} M). Control cultures received 0.2% solvent. At the end of incubation the cells were counted and assayed for survival by eosin Y exclusion. IC₅₀ values were determined from the dose–response curves by graphical interpolation. Each compound was tested in three separate experiments, each experiment included controls with and without $1\alpha,25(\text{OH})_2\text{D}_3$, and all cultures were performed in triplicate. A sample of cells from each culture was fixed with formalin and cell differentiation was assessed by staining for membrane-associated non-specific esterase by the method of Yam *et al.* [19]. The cells were scored under microscope and induction of cell differentiation was recorded as the lowest concentration of test compound giving a 3-fold increase in the number of esterase-positive cells, compared to control cultures (control cultures containing $6 \pm 2\%$ differentiated cells). Additional studies on cell proliferation were performed using the human breast carcinoma cell line T-47D (ATCC HTB 133) and the rat osteosarcoma cell line M1-OS/C42 (kindly provided by Dr T. Klenner, Deutsches Krebsforschungszentrum, Heidelberg, Germany). The cells were adjusted to 5×10^4 cells/mL in medium RPMI 1640, as described above for the U 937 cells, and cultured for 7 days in the presence of $1\alpha,25(\text{OH})_2\text{D}_3$ or KH 1060 (10^{-13} – 10^{-7} M). Fresh medium and test compounds were added on day 4 of culture. Inhibition of cell proliferation was assessed by uptake of [³H]thymidine ([³H]TdR, 1 µCi/ml, 5 Ci/mmol, Amersham, U.K.) during the last 4 hr of culture. IC₅₀ values were determined from the dose–response curves. Three separate experiments were performed, with each concentration tested in quadruplicate.

Effects on T-cell activation in vitro. Studies on T-cell activation were performed using the mouse thymocyte co-stimulatory assay [20] and the mixed lymphocyte reaction (MLR) between allogeneic mouse spleen cells [21]. Thymocytes were prepared from the thymus of 4–6-week-old Balb/c mice and adjusted to 5×10^6 cells/mL in RPMI 1640, supplemented with 5% FCS. Samples of 200 µL cells were cultured in the presence of interleukin-1 or interleukin-2 (IL-1, 2.5 units/mL; IL-2, 20 units/mL), Boehringer, Mannheim, Germany) and phytohemagglutinin-P (PHA, 10 µg/mL, Sigma Chemical Co., MO, U.S.A.) for 72 hr. For the MLR cultures, spleen cells were prepared from Balb/c and CB6F₁ mice and adjusted to 2.5×10^6 cells/mL. Cultures containing 100 µL of each cell suspension were incubated for 144 hr. Selected cultures were supplemented with high concentrations of IL-2 (250 units/mL). Solvent, vitamin D₃ derivatives or

CyA were added at the start of incubation (max. solvent concentration 0.04%). Proliferation was assessed by [³H]TdR uptake (1 µCi/mL) during the last 4 hr of incubation. Each compound was tested in three separate experiments and all cultures were performed in triplicate.

Effects on cytokine release in vitro. Mononuclear cells were obtained from the peripheral venous blood of healthy volunteers by density centrifugation with Lymphoprep® (Nycomed, Norway). For assay of IL-1 release, the cells were adjusted to 1.5×10^6 cells/mL in RPMI 1640 supplemented with 1% autologous human serum. The cells were stimulated with 2 µg/mL lipopolysaccharide (LPS from *E. coli*, Difco, U.S.A.) for 24 hr, in the presence of vitamin D₃ analogues. IL-1 in cell supernatants was determined by radioimmunoassay (RIA) (RPA 533, Amersham, U.K.). For assay of IL-2 release, mononuclear cells were adjusted to 2.5×10^6 cells/mL in RPMI 1640, supplemented with 2% FCS, and stimulated with 20 µg/mL PHA, in the presence of vitamin D₃ analogues, for 24 hr. IL-2 release was quantitated using cultures of CD3⁺ T-lymphocytes, selected from human blood mononuclear cells by particle-bound anti-CD3 monoclonal antibody (Immunotech, France), as described by Leivestad *et al.* [22]. The specificity of the released IL-2 was verified by addition of antibodies to IL-2 (rabbit anti-human IL-2 polyclonal antibody, 50 µg/mL, Genzyme, U.S.A.). All cultures were performed in triplicate. Concentrations of vitamin D₃ derivatives resulting in 50% inhibition of cytokine release were calculated.

Receptor binding studies. Receptor protein from the intestinal epithelium of rachitic chickens was purchased from Amersham, U.K. (TRK.870). Samples of 500 µL were incubated with 10,000 dpm [³H] $1\alpha,25(\text{OH})_2\text{D}_3$ (180 Ci/mmol, Amersham, U.K.) and increasing concentrations of $1\alpha,25(\text{OH})_2\text{D}_3$ or vitamin D₃ analogues were added. After incubation for 60 min at 22°, bound and free [³H] $1\alpha,25(\text{OH})_2\text{D}_3$ were separated on dextran-coated charcoal. The concentration resulting in 50% displacement of bound [³H] $1\alpha,25(\text{OH})_2\text{D}_3$ was calculated. Each compound was tested in three separate experiments.

Receptor protein was prepared from cultures of U 937, T-47D and M1-OS/C42 cells. Suspensions of 5×10^7 cells/mL were homogenized, sonicated and centrifuged at 30,000 g for 1 hr at 4°. The presence of the $1\alpha,25(\text{OH})_2\text{D}_3$ receptor was checked by sucrose density gradient analysis as described by Colston *et al.* [23]. The supernatants were adjusted to 2 mg protein/mL and used for binding studies with $1\alpha,25(\text{OH})_2\text{D}_3$ and KH 1060 as described above for the chicken intestinal receptor.

Effects on calcium metabolism in vivo. Calcemic effects of the vitamin D₃ derivatives were assessed in female, inbred Lewis rats (140–160 g), replete in vitamin D and receiving a standard laboratory diet containing 1% calcium and 0.75% phosphorus. Hypercalciuria was chosen as the most sensitive test parameter of vitamin D-like activity. Test compounds were given orally at 0.1, 1.0 and 10 µg/kg/day, for 7 days. Control rats received the vehicle (propylene glycol) and each experiment included a group treated with $1\alpha,25(\text{OH})_2\text{D}_3$ (0.5 µg/kg/day). Each group

vitamin D₃ derivatives was expertly provided by the technicians in the Department of Chemical Research. For the biological testing, the authors wish to thank Ms B. Hasselriis, Ms L. Rohde, Ms D. Hansen and Ms H. Olsen.

REFERENCES

- Reichel H, Koffler HP and Norman AW, The role of vitamin D endocrine system in health and disease. *N Engl J Med* 320: 980-991, 1989.
- Minghetti PP and Norman AW, 1,25(OH)₂-Vitamin D₃ receptors: gene regulation and genetic circuitry. *FASEB J* 2: 3043-3053, 1988.
- DeLuca HF, Krisinger J and Darwish H, The vitamin D system: 1990. *Kidney Int* 38: S2-S8, 1990.
- Smith EL, Pincus SH, Donovan L and Holick MF, A novel approach for the evaluation and treatment of psoriasis. *J Am Acad Dermatol* 19: 516-528, 1988.
- Morimoto S, Yoshikawa K, Kozuka T, Kitano Y, Imanaka S, Fukuo K, Koh E and Kumahara Y, An open study of vitamin D₃ treatment in psoriasis vulgaris. *Br J Dermatol* 115: 421-429, 1986.
- Cunningham D, Gilchrist NL, Cowan RA, Forrest GJ, McArdle CS and Soukop M, Alfalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. *Br Med J* 291: 1153-1155, 1985.
- Vieth R, The mechanisms of vitamin D toxicity. *Bone Mineral* 11: 267-272, 1990.
- Calverley MJ, Synthesis of MC 903, a biologically active vitamin D metabolite analogue. *Tetrahedron* 43: 4609-4619, 1987.
- Binderup L and Bramm E, Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiation *in vitro* and on calcium metabolism *in vivo*. *Biochem Pharmacol* 37: 889-895, 1988.
- Binderup L, MC 903—a novel vitamin D₃ analogue with potent effects on cell proliferation and cell differentiation. In: *Vitamin D. Molecular, Cellular and Clinical Endocrinology* (Eds. Norman AW, Schaefer K, Grigoleit HG and Herrath D), pp. 300-309. Walter de Gruyter, Berlin, 1988.
- Kragballe K, Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). *Arch Dermatol* 125: 1647-1652, 1989.
- Kragballe K, Gjertsen BT, de Hoop D, Karlsmark T, van de Kerkhof PCM, Larkö O, Nieboer C, Roed-Petersen J, Strand A and Tikjøb G, Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. *Lancet* 337: 193-196, 1991.
- Zhou JY, Norman AW, Chen DL, Sun G, Uskokovic M and Koeffler HP, 1,25-Dihydroxy-16-ene-23-yne-vitamin D₃ prolongs survival of leukemic mice. *Proc Natl Acad Sci USA* 87: 3929-3932, 1990.
- Abe J, Takita Y, Nakano T, Miyaura C, Suda T and Nishii Y, A synthetic analogue of vitamin D₃, 22-oxa-1 α ,25-dihydroxy-vitamin D₃, is a potent modulator of *in vivo* immunoregulating activity without inducing hypercalcemia in mice. *Endocrinology* 124: 2645-2647, 1989.
- Dodd RC, Cohen MS, Newman SL and Grey TK, Vitamin D metabolites change the phenotype of monoblastic U 937 cells. *Proc Natl Acad Sci USA* 80: 7538-7541, 1983.
- Manolagas SC, Hustmyer FG and Yu XP, Immunomodulating properties of 1,25-dihydroxyvitamin D₃. *Kidney Int* 38: S9-S16, 1990.
- Koizumi T, Nakao Y, Matsui T, Nakagawa T, Katakami Y and Fujita T, Effect of 1,25-dihydroxyvitamin D₃ on cytokine-induced thymocyte proliferation. *Cell Immunol* 96: 455-461, 1985.
- Gupta S, Fass D, Shimizu M and Vayuvegula B, Potentiation of immunosuppressive effects of cyclosporin A by 1 α ,25-dihydroxyvitamin D₃. *Cell Immunol* 121: 290-297, 1989.
- Yam LT, Liand CY and Crosby WH, Cytochemical identification of monocytes and granulocytes. *Am J Clin Pathol* 55: 283-290, 1971.
- Rosenwasser LJ and Dinarello CA, Ability of human leucocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation. *Cell Immunol* 63: 134-142, 1981.
- Bhalla AK, Amento EP, Serog B and Glimcher LH, 1,25-Dihydroxyvitamin D₃ inhibits antigen-induced T cell activation. *J Immunol* 133: 1748-1754, 1984.
- Leivestad T, Gaudernack G, Halvorsen R and Thorsby E, A simple and sensitive bioassay for the detection of IL-2 activity. *J Immunol Methods* 114: 95-99, 1988.
- Colston K, Coston J, Fieldsteel AH and Feldman D, 1,25-Dihydroxyvitamin D₃ receptors in human epithelial cancer cell lines. *Cancer Res* 42: 856-859, 1982.
- Dinarello CA, Biology of interleukin 1. *FASEB J* 2: 108-115, 1988.
- Ikekawa N, Structures and biological activities of vitamin D metabolites and their analogs. *Med Res Rev* 7: 333-366, 1987.
- Inaba M, Okuno S, Inoue A, Nishizawa Y, Morii H and DeLuca HF, DNA binding property of vitamin D₃ receptors associated with 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D₃. *Arch Biochem Biophys* 268: 35-39, 1989.
- Martin DL and DeLuca HF, Influence of sodium on calcium transport by the rat small intestine. *Am J Physiol* 216: 1351-1359, 1969.
- Hibberd KA and Norman AW, Comparative biological effects of vitamins D₂ and D₃ and dihydrotachysterol₂ and dihydrotachysterol₁ in the chick. *Biochem Pharmacol* 18: 2347-2355, 1969.
- Padova FE, Pharmacology of Cyclosporine (Sandimmune). V. Pharmacological effects on immune function: *In vitro* studies. *Pharmacol Rev* 41: 373-405, 1989.
- Amento EP, Vitamin D and the immune system. *Steroids* 49: 55-72, 1987.
- Muller K, Svenson M and Bendtzen K, 1 α ,25-Dihydroxy-vitamin D₃ and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 *in vitro*. *Immunology Lett* 17: 361-366, 1988.
- Vanhan G, Ceuppens JL and Bouillon R, T-lymphocytes and their CD4 subsets are direct targets for the inhibitory effect of calcitriol. *Cell Immunol* 124: 320-333, 1989.
- Harding MW and Handschumacher, Cyclosporin and its receptor, cyclophilin. In: *Advances in Inflammation Research* (Ed. Lewis A), pp. 283-294. Raven Press, New York, 1988.
- Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E and Crabtree GR, Cyclosporin A specifically inhibits function of nuclear proteins in T cell activation. *Science* 246: 1617-1620, 1989.
- Matsui T, Takahashi R, Nakao Y, Koizumi T, Katakami Y, Mihara K, Sugiyama T and Fujita T, 1,25-Dihydroxyvitamin D₃-regulated expression of genes involved in human T-lymphocyte proliferation and differentiation. *Cancer Res* 46: 5827-5831, 1986.
- Colombani PM and Hess AD, T-lymphocyte inhibition by cyclosporine: Potential mechanisms of action. *Biochem Pharmacol* 36: 3789-3793, 1987.
- Bar S, Lidor C, Harell A and Edelstein S, Influence of 1,25-hydroxyvitamin D₃ on cytosolic free calcium concentrations. *Biochem Biophys Res Commun* 141: 1236-1241, 1986.